This is great news for hospices and their patients, who are already feeling the effects of the ban with severe shortages of morphine in some areas. The FDA has contacted the manufacturers of the morphine solutions and informed them of the amendment so we should be seeing some relief soon.
This amendment allows manufacturers more time to prove to the FDA the safety, quality, and effectiveness of the morphine solution. This amendment only covers the liquid concentration of the drug and not the tablets that were included. For more information, visit the FDA's website.